Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 2,402 Shares

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CEO Emily M. Leproust sold 2,402 shares of the business's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $98,265.82. Following the completion of the transaction, the chief executive officer now owns 662,692 shares in the company, valued at $27,110,729.72. This represents a 0.36 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Twist Bioscience Stock Performance

TWST stock traded up $0.65 during trading on Friday, reaching $39.77. 396,260 shares of the company's stock were exchanged, compared to its average volume of 992,561. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The firm has a market cap of $2.37 billion, a PE ratio of -11.77 and a beta of 2.15. The company's fifty day moving average price is $45.91 and its 200-day moving average price is $45.31. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Twist Bioscience's revenue was up 24.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.75) EPS. On average, research analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors have recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Twist Bioscience in the third quarter valued at $34,000. Van ECK Associates Corp raised its position in Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after acquiring an additional 267 shares in the last quarter. Banque Transatlantique SA acquired a new stake in Twist Bioscience in the 4th quarter valued at about $43,000. GF Fund Management CO. LTD. bought a new position in shares of Twist Bioscience during the 4th quarter valued at about $58,000. Finally, US Bancorp DE grew its stake in shares of Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after purchasing an additional 601 shares during the last quarter.

Analyst Upgrades and Downgrades

TWST has been the subject of a number of recent analyst reports. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird raised their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 4th. JPMorgan Chase & Co. boosted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. Barclays set a $58.00 price target on Twist Bioscience and gave the stock an "overweight" rating in a report on Monday, February 3rd. Finally, TD Cowen reaffirmed a "buy" rating and issued a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Twist Bioscience currently has a consensus rating of "Moderate Buy" and a consensus price target of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.